EL7.AI
StocksMedium•16 November 2026•
4 min read

Adagio Medical Posts $17.8 Million Quarterly Profit on Noncash Gain

Key Facts

1Adagio Medical reported net income of $17.8 million in the third quarter of 2026, compared with a $10.1 million loss a year earlier.
2The result stemmed mainly from a noncash gain of $23.0 million from changes in the fair value of notes carrying 13% interest.
3The company recorded no revenue in the third quarter of 2026 or the year-earlier period.
4Cash and cash equivalents totaled $3.1 million on September 30, 2026, compared with $17.1 million on December 31, 2025.
5The company said cash would fund planned expenses through the first quarter of 2027, but would not cover at least 12 months of operations.

Adagio Medical reported net income of $17.8 million for the three months ended September 30, 2026, compared with a net loss of $10.1 million in the year-earlier period, according to a filing with the U.S. Securities and Exchange Commission. The company attributed the result mainly to a noncash gain of $23.0 million from changes in the fair value of its secured convertible notes, which carry annual interest of 13%. The company recorded no revenue in either period. It remained loss-making at the operating level, although its operating loss narrowed to $4.4 million from $5.7 million a year earlier. Net income therefore reflects an accounting change tied to the valuation of the notes, while operations remain revenue-free and loss-making.

The comparison between net income and operating loss shows the effect of the noncash gain on the quarter's result. The company reported a net loss of $28.3 million for the nine months ended September 30, 2026, compared with $23.6 million in the same period of 2025. Its operating activities used $14.0 million in cash during the first nine months of the year, compared with $14.9 million in the year-earlier period. This means operating cash use declined year over year even as the net loss widened for the same period. The absence of revenue also makes funding spending and continuing product development a direct financial focus for the company.

Cash and cash equivalents totaled $3.1 million on September 30, 2026, down from $17.1 million on December 31, 2025, according to the filing. The company had reported liquidity of $7.7 million on June 30, 2026, compared with the same $17.1 million at the end of 2025. The sequence of balances shows cash declining during the first nine months, while quarterly revenue remained unchanged at zero. The company said its liquidity, under current plans, is expected to fund planned expenses through the first quarter of 2027. It clarified, however, that its cash is insufficient to fund operations for at least 12 months from the date the financial statements were issued.

Adagio warned that its liquidity position raises "substantial doubt" about its ability to continue as a going concern. The warning comes as operating losses continue and revenue remains absent, despite the reported quarterly net income. In September, the company began a formal review of strategic alternatives aimed at maximizing shareholder value, saying the options could include an acquisition, merger or other transaction. In a November 10 update, it said the board had not set a definitive timetable for completing the review and there was no assurance it would result in any particular transaction. The outcome of the review and future sources of financing therefore remain critical to the company's path beyond its stated liquidity horizon.

The review of options coincided with a reduction in the company's workforce to 18 full-time employees from 43, effective September 23, 2026. On products, the CEO said the ventricular vCLAS system's marketing approval application remains under review by the U.S. Food and Drug Administration, and that the company had begun an IDE study for the vCLAS Ultra system. In its November 10 update, the company said 22 patients had received vCLAS Ultra at seven centers in the United States and Canada; 19 were participants in the FULCRUM-VT sub-study and three were compassionate-use cases. It added that physicians had observed a reduction in ablation times of more than 60% compared with the first-generation system. It also said enrollment in the pivotal FULCRUM-VT study had reached 209 patients, and that the commercial vCLAS system is available in Europe and selected markets, while its use in the United States is limited to research.

In a development related to the stock's trading, the company completed a 1-for-30 reverse stock split on November 6, with split-adjusted trading beginning on November 9, 2026. Adagio shares, listed under the ticker ADGM, closed at $1.93 on November 13, according to EL7 data. The closing price followed the start of split-adjusted trading, while the available price data did not include reliable session highs and lows. These financial and clinical developments leave the company pursuing two parallel paths: completing its review of alternatives and advancing the regulatory process for its products. The company has set no deadline for the review, while the vCLAS application remains under regulatory review.

Open on chart